2020
DOI: 10.1111/dth.14430
View full text
|
Sign up to set email alerts
|
Share

Abstract: A previous clinical study suggested that dabrafenib plus trametinib (D + T) combination therapy could cause a high rate of various AEs including skin disorders in BRAF V600E mutated advanced melanoma patients. 1 Indeed, 24% (50/209) of patients treated with D + T combination therapy developed skin disorders. 1

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals